干扰素-γ释放试验作为系统性红斑狼疮中新兴强效生物标志物的研究
该回顾性研究纳入145例不同疾病阶段的系统性红斑狼疮(SLE)患者,探讨体外IFN-γ释放试验(IGRA)作为SLE活动性和疾病结局生物标志物的价值。研究发现活动期SLE患者自发IFN-γ释放增高(IGRA-nil,P=0.0004)而PHA诱导的IFN-γ释放降低(IGRA-PHA,P<10^-4);IGRA-PHA≥8.0 IU/ml独立预测临床非活动性SLE(OR=10.6,95%CI 3.72-30.17),IGRA-PHA≤1.6 IU/ml与达到缓解时间更长相关(log-rank P=2.4×10^-6)。
要点
- 活动期SLE患者自发IFN-γ释放增高而PHA诱导IFN-γ释放降低,不受治疗包括糖皮质激素影响。
- IGRA-PHA≥8.0 IU/ml独立预测临床非活动性SLE(OR=10.6,95%CI 3.72-30.17,P=9.7×10^-6)。
- IGRA-PHA≤1.6 IU/ml与达到缓解时间更长相关(log-rank P=2.4×10^-6)。
核心结论
- IGRA-PHA检测似乎在治疗起始或强化时是临床活动性SLE的强效独立生物标志物,并在治疗评估时预测治疗诱导的缓解。
研究设计与样本
- 本研究为回顾性研究,于2008年至2024年在单一三级医疗中心开展,纳入145例不同疾病阶段的SLE患者,收集自发IFN-γ水平(IGRA-nil)和植物血凝素诱导的IFN-γ水平(IGRA-PHA,减去IGRA-nil结果后)数据。
主要发现
- 活动期SLE患者自发IFN-γ释放增高(IGRA-nil,P=0.0004),PHA诱导的IFN-γ释放降低(IGRA-PHA,P<10^-4),且不受治疗包括糖皮质激素影响。
- 肾炎、浆膜炎、全身症状、黏膜皮肤和肌肉骨骼表现均与IGRA-PHA释放受损相关(每种关联P<0.05)。
- IGRA-PHA≥8.0 IU/ml(对应最佳约登指数)预测临床非活动性SLE优于IGRA-nil(曲线下面积=0.853 vs 0.722),IGRA-PHA<1.6 IU/ml对活动性疾病显示100%特异性。
- 多变量回归分析中,IGRA-PHA≥8.0 IU/ml是临床非活动性SLE的独立预测因子(OR=10.6,95%CI 3.72-30.17,P=9.7×10^-6),IGRA-PHA≤1.6 IU/ml在log-rank检验中与达到缓解时间更长相关(P=2.4×10^-6)。
关键数值与推荐
- IGRA-PHA≥8.0 IU/ml对应最佳约登指数,预测临床非活动性SLE的曲线下面积为0.853,IGRA-nil为0.722。
- IGRA-PHA<1.6 IU/ml对活动性疾病显示100%特异性。
- IGRA-PHA≥8.0 IU/ml独立预测临床非活动性SLE的OR=10.6(95%CI 3.72-30.17),P=9.7×10^-6。
- IGRA-PHA≤1.6 IU/ml与达到缓解时间更长相关的log-rank检验P=2.4×10^-6。
临床怎么用
- 作者认为IGRA-PHA检测可在治疗起始或强化时用于评估临床活动性SLE,并在治疗评估时预测治疗诱导的缓解。
局限性
- 本研究为回顾性研究,在单一三级医疗中心开展。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To investigate the ex vivo IFN-γ release assay (IGRA) as a biomarker of systemic lupus erythematosus (SLE) activity and disease outcome. METHODS: This retrospective study, conducted between 2008 and 2024 at a single tertiary care centre, included 145 SLE patients at various disease stages. Data were collected on spontaneous IFN-γ levels (IGRA-nil) and on phytohemagglutinin-induced IFN-γ levels (IGRA-PHA, after subtracting the IGRA-nil result). RESULTS: The ex vivo spontaneous IFN-γ release was increased (IGRA-nil; P = 0.0004) and the PHA-induced IFN-γ release was decreased in active SLE patients (IGRA-PHA; P < 10-4), regardless of treatment, including glucocorticoids. Nephritis, serositis, constitutional symptoms, mucocutaneous and musculoskeletal manifestations were associated with impaired IGRA-PHA release (P < 0.05 for each association). An IGRA-PHA ≥ 8.0 IU/ml, corresponding to the optimal Youden index, predicted clinically inactive SLE better than IGRA-nil (area under the curve = 0.853 vs 0.722) and IGRA-PHA <1.6 IU/ml indicated 100% specificity for active disease. Moreover, IGRA-PHA ≥ 8.0 IU/ml was an independent predictor of clinically inactive SLE in multivariate regression analysis (OR: 10.6 [95% CI: 3.72-30.17]; P = 9.7 × 10-6), and IGRA-PHA ≤1.6 IU/ml was associated with a longer time to achieve remission in a log-rank test (P = 2.4 × 10-6). CONCLUSION: The IGRA-PHA assay appears to be a powerful and independent biomarker for clinically active SLE, when performed at the initiation or intensification of therapy, and as a predictor of treatment-induced remission at therapy evaluation.
引用
- Renaudineau Y, Treiner E, Herin F, et al. Interferon-γ release assay as an emergent powerful biomarker in systemic lupus erythematosus. Rheumatology (Oxford). 2025. PMID: 40440161. doi:10.1093/rheumatology/keaf186
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。